Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine

BACKGROUND: Although clinical trials testing immunotherapies in glioblastoma (GBM) have yielded mixed results, new strategies targeting tumor-specific somatic coding mutations, termed “neoantigens,” represent promising therapeutic approaches. We characterized the microenvironment and neoantigen land...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Liu, Connor J, Schaettler, Maximilian, Blaha, Dylan T, Bowman-Kirigin, Jay A, Kobayashi, Dale K, Livingstone, Alexandra J, Bender, Diane, Miller, Christopher A, Kranz, David M, Johanns, Tanner M, Dunn, Gavin P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Basic and Translational Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523441/
https://ncbi.nlm.nih.gov/pubmed/32133512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa050
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars